Peter the Bridge, Saint Petersburg, Russia

The NEOMED Institute is Attending the 23rd Annual BioEurope Partnering Conference

22 November 2017|Announcement| No Comments

NEOMED’s 3 key partnering objectives:

• Identify licensing partners/financial partners for NEOMED’s therapeutic pipeline
• Identify promising in-licensing opportunities
• Showcase NEOMED Innovation Center’s expansion project

Montreal, October 25th, 2017 – The NEOMED Institute announced today that it will attend the 23rd Annual BioEurope Partnering Conference, Europe’s largest life science partnering conference that will be held in Berlin, Germany, November 6-8, 2017.

“BioEurope 2017 is a tremendous venue for NEOMED to showcase its programs to potential partners, as well as, to identify interesting and innovative new opportunities to replenish our pipeline,” said Donald Olds (President & CEO). “Both Daniel Böck (VP Business Development) and I will be participating in the event and remain available to meet with companies interested in connecting with NEOMED to discuss partnership structures around our current therapeutic pipeline assets as well as to review new potential in-licensing opportunities.”

In addition, Pierre-Yves Desbiens (Chief Operating Officer) will be attending to represent NEOMED’s Innovation Center and meet with companies interested in learning more about becoming a part of
Montreal’s largest life sciences ecosystem as well as getting access to our state-of-the-art facilities. “I am very excited to attend BioEurope 2017 and to meet with companies across the globe that are interested in learning more about the laboratories and services that we can offer to biotechnology and CRO companies interested in expanding their presence and activities in North America,” declared Mr. Desbiens.

About NEOMED Institute

NEOMED Institute is a not‐for‐profit organization whose mission is to bridge the gap between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with the creation of a vibrant and sustainable life science ecosystem. NEOMED operates two fully integrated research and development campuses in Montreal: one specializing in small molecule therapeutics, and the other specializing in the development of biologics and vaccines. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses (30 independent companies employing more than 300 people) and providing a dynamic environment that stimulates collaboration, innovation, and creativity. NEOMED’s wholly-owned for-profit subsidiary, NEOMED-LABS, a Contract Research Organization (CRO) providing customized and high-throughput immune-monitoring for clinical vaccine development, is one of these tenants. NEOMED is jointly funded by our pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website:
www.neomed.ca

For more information, please contact:

NEOMED Institute
Donald Olds
President & CEO
7171 Frederick-Banting
Montreal, Quebec, Canada
H4S 1Z9
dolds@neomed.ca

NEOMED Innovation Center
Pierre-Yves Desbiens,
Chief Operating Officer
7171 Frederick-Banting
Montreal, Quebec, Canada
H4S 1Z9
pydesbiens@neomed.ca

Share this

Leave a Reply

Similar News

image articles
20 September 2017

NEO6860 Clinical Results to be Presented at the Pain & Migraine Therapeutics Summit

Read complete news
image articles
18 September 2017

PARG Inhibitor Collaboration – BioAuxilium and NEOMED

Read complete news
© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia